Pelthos Therapeutics (PTHS) Stock: Buy, Sell, or Hold?
PTHS - Pelthos Therapeutics Inc.
$21.90
-0.53 (-2.36%)
▼
5d:
-10.1%
30d:
-24.25%
90d:
-23.75%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When PTHS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PTHS is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PTHS is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PTHS is currently trading at $21.90, which is considered oversold relative to its 30-day fair value range of $24.09 to $28.14.
Technical Outlook: Technically, PTHS is showing sideways momentum. Immediate support is located at $21.21, while resistance sits at $26.10.
Market Sentiment: PTHS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.14 (+142.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PTHS is showing sideways momentum. Immediate support is located at $21.21, while resistance sits at $26.10.
Market Sentiment: PTHS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.14 (+142.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.09 -
$28.14
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 142.7% below Wall St target ($53.14)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.09 -
$28.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.21
Resistance Level
$26.10
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.85
Wall Street Target
$53.14
(+142.7%)
Profit Margin
-199.5%
Share & Embed Analysis
Last updated: September 12, 2026 5:33 PM ET
Data refreshes hourly during market hours. Next update: 6:33 PM
Data refreshes hourly during market hours. Next update: 6:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTHS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ezra M Friedberg
SELL
558 shares
2026-04-02
Peter Greenleaf
SELL
797 shares
2026-04-02
Richard Malamut
SELL
590 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
